Related Experiment Video
Updated: Jun 8, 2026
07:38
Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Rituximab for steroid-dependent nephrotic syndrome
A Beco1, I Castro-Ferreira, L Coentrao
1Nephrology Research and Development Unit, Faculty of Medicine, University of Porto and Hospital de S. Joao EPE, Alameda Prof. Hernani Monteiro, Porto, Portugal. coentrao@med.up.pt
Clinical Nephrology
|September 30, 2010
Summary
Minimal change disease (MCD) often relapses, requiring toxic treatments. Rituximab provided a sustained remission for one year in an adult patient with steroid-dependent MCD, offering a potentially less toxic therapeutic option.
Area of Science:
- Nephrology
- Immunology
Background:
- Minimal change disease (MCD) is a primary cause of nephrotic syndrome, typically responsive to glucocorticoids.
- However, a significant proportion of patients experience frequent relapses or become steroid-dependent, necessitating prolonged or intensified immunosuppressive therapy.
- Current treatment strategies aim for sustained remission with minimized toxicity due to the adverse effects of long-term immunosuppression.
Observation:
- This case report details an adult patient with a long-standing history of steroid-dependent MCD since childhood.
- The patient had undergone multiple courses of various immunosuppressive agents, including azathioprine, cyclophosphamide, and cyclosporine, with limited success.
Findings:
- Two infusions of rituximab (375 mg/m2) induced a sustained remission of proteinuria lasting one year.
- This outcome was achieved in a patient with a complex history of treatment resistance and steroid dependency.
Implications:
- Rituximab demonstrates potential as an effective and possibly less toxic therapeutic option for difficult-to-treat cases of minimal change disease.
- Further research into rituximab's role in managing idiopathic nephrotic syndrome, particularly in steroid-dependent or frequently relapsing cases, is warranted.
- This case highlights the utility of targeted B-cell depletion in achieving long-term remission in refractory MCD.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
01:24Nephrotic Syndrome I : Introduction
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:24Nephrotic Syndrome III : Nursing Management
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...